Foster Dykema Cabot & Partners LLC Buys 2,173 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Foster Dykema Cabot & Partners LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 45,312 shares of the medical research company’s stock after acquiring an additional 2,173 shares during the period. Thermo Fisher Scientific accounts for 1.8% of Foster Dykema Cabot & Partners LLC’s portfolio, making the stock its 20th largest holding. Foster Dykema Cabot & Partners LLC’s holdings in Thermo Fisher Scientific were worth $23,590,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. Pillar Financial Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Down 0.9 %

Shares of Thermo Fisher Scientific stock opened at $436.90 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $409.85 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a market cap of $164.93 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 2.99 and a beta of 0.86. The firm’s 50-day moving average is $502.59 and its two-hundred day moving average is $536.26.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is 10.41%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a research report on Friday, January 10th. UBS Group raised their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Raymond James reaffirmed an “outperform” rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.